Investigation of newborns with abnormal results in a newborn screening program for four lysosomal storage diseases in Brazil

• Published in: Molecular genetics and metabolism reports Vol. 12; no. C; pp. 92 - 97
• Main Authors: Bravo, Heydy, Neto, Eurico Camargo, Schulte, Jaqueline, Pereira, Jamile, Filho, Claudio Sampaio, Bittencourt, Fernanda, Sebastião, Fernanda, Bender, Fernanda, de Magalhães, Ana Paula Scholz, Guidobono, Régis, Trapp, Franciele Barbosa, Michelin-Tirelli, Kristiane, Souza, Carolina F.M., Rojas Málaga, Diana, Pasqualim, Gabriela, Brusius-Facchin, Ana Carolina, Giugliani, Roberto
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-09-2017; Elsevier
• Subjects: Brazil; Carrier; Confirmatory diagnosis; Lysosomal storage diseases; Newborn screening; Pseudodeficiency; Research Paper; Newborn screening; Brazil; Lysosomal storage diseases; Carrier; Pseudodeficiency; Confirmatory diagnosis
• ISSN: 2214-4269; 2214-4269
• DOI: 10.1016/j.ymgmr.2017.06.006

Lysosomal storage diseases (LSDs) are genetic disorders, clinically heterogeneous, mainly caused by defects in genes encoding lysosomal enzymes that degrade macromolecules. Several LSDs already have specific therapies that may improve clinical outcomes, especially if introduced early in life. With this aim, screening methods have been established and newborn screening (NBS) for some LSDs has been developed. Such programs should include additional procedures for the confirmation (or not) of the cases that had an abnormal result in the initial screening. We present here the methods and results of the additional investigation performed in four babies with positive initial screening results in a program of NBS for LSDs performed by a private laboratory in over 10,000 newborns in Brazil. The suspicion in these cases was of Mucopolysaccharidosis I - MPS I (in two babies), Pompe disease and Gaucher disease (one baby each). One case of pseudodeficiency for MPS I, 1 carrier for MPS I, 1 case of pseudodeficiency for Pompe disease and 1 carrier for Gaucher disease were identified. This report illustrates the challenges that may be encountered by NBS programs for LSDs, and the need of a comprehensive protocol for the rapid and precise investigation of the babies who have an abnormal screening result.